Browse > Article
http://dx.doi.org/10.1016/j.jgr.2022.01.002

COVID-19 and Panax ginseng: Targeting platelet aggregation, thrombosis and the coagulation pathway  

Lee, Yuan Yee (Ginseng Circulatonic Laboratory, College of Veterinary Medicine, Kyungpook National University)
Quah, Yixian (Development and Reproductive Toxicology Research Group, Korea Institute of Toxicology)
Shin, Jung-Hae (Ginseng Circulatonic Laboratory, College of Veterinary Medicine, Kyungpook National University)
Kwon, Hyuk-Woo (Department of Biomedical Laboratory Science, Far East University)
Lee, Dong-Ha (Department of Biomedical Laboratory Science, Namseoul University)
Han, Jee Eun (College of Veterinary Medicine, Kyungpook National University)
Park, Jin-Kyu (College of Veterinary Medicine, Kyungpook National University)
Kim, Sung Dae (College of Veterinary Medicine, Kyungpook National University)
Kwak, Dongmi (College of Veterinary Medicine, Kyungpook National University)
Park, Seung-Chun (College of Veterinary Medicine, Kyungpook National University)
Rhee, Man Hee (Ginseng Circulatonic Laboratory, College of Veterinary Medicine, Kyungpook National University)
Publication Information
Journal of Ginseng Research / v.46, no.2, 2022 , pp. 175-182 More about this Journal
Abstract
Coronavirus disease 2019 (COVID-19) not only targets the respiratory system but also triggers a cytokine storm and a series of complications, such as gastrointestinal problems, acute kidney injury, and myocardial ischemia. The use of natural products has been utilized to ease the symptoms of COVID-19, and in some cases, to strengthen the immune system against COVID-19. Natural products are readily available and have been regularly consumed for various health benefits. COVID-19 has been reported to be associated with the risk of thromboembolism and deep vein thrombosis. These thrombotic complications often affects mortality and morbidity. Panax ginseng, which has been widely consumed for its various health benefits has also been reported for its therapeutic effects against cardiovascular disease, thrombosis and platelet aggregation. In this review, we propose that P. ginseng can be consumed as a supplementation against the various associated complications of COVID-19, especially against thrombosis. We utilized the network pharmacology approach to validate the potential therapeutic properties of P. ginseng against COVID-19 mediated thrombosis, the coagulation pathway and platelet aggregation. Additionally, we aimed to investigate the roles of P. ginseng against COVID-19 with the involvement of platelet-leukocyte aggregates in relation to immunity-related responses in COVID-19.
Keywords
Panax ginseng; Coagulation; Thrombosis; Platelet aggregation; COVID-19;
Citations & Related Records
Times Cited By KSCI : 12  (Citation Analysis)
연도 인용수 순위
1 Fuzimoto AD, Isidoro C. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds-Additional weapons in the fight against the COVID-19 pandemic? J Tradit Complement Med 2020;10(4):405-19.   DOI
2 Smeda M, Chlopicki S. Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter? Cardiovasc Res 2020;116(10):e118-21.
3 Irfan M, Lee YY, Lee K-J, Kim SD, Rhee MH. Comparative antiplatelet and antithrombotic effects of red ginseng and fermented red ginseng extracts. J Ginseng Res 2021. Article in Press.
4 Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res 2020;127(11):1404-18.   DOI
5 Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 2020;182(1):59-72.   DOI
6 Vulliamy P, Jacob S, Davenport RA. Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19. Br J Haematol 2020;189(6):1053-4.   DOI
7 Xu X, Chang X, Pan H, Su H, Huang B, Yang M, et al. Pathological changes of the spleen in ten patients with new coronavirus infection by minimally invasive autopsies. Chin J Pathol 2020;49(6):576-82.
8 Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MC, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemostasis 2020;18(8):1995-2002.   DOI
9 Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID-19. Am J Hematol 2020;95(12):1578-89.   DOI
10 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemostasis 2020;18(4):844-7.   DOI
11 Nuyttens BP, Thijs T, Deckmyn H, Broos K. Platelet adhesion to collagen. Thromb Res 2011;127:S26-9.
12 Wichmann D, Sperhake J-P, Lutgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020;173(4):268-77.   DOI
13 Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020;191:148-50.   DOI
14 Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 2019;133(9):906-18.   DOI
15 Nicolai L, Gaertner F, Massberg S. Platelets in host defense: experimental and clinical insights. Trends Immunol 2019;40(10):922-38.   DOI
16 Stocker TJ, Hellen I-A, Steffen M, Christian S. Small but mighty: platelets as central effectors of host defense. Thromb Haemostasis 2017;117(4):651-61. 0.   DOI
17 Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 2006;37(3):208-22.   DOI
18 Olwal CO, Nganyewo NN, Tapela K, Djomkam Zune AL, Owoicho O, Bediako Y, et al. Parallels in sepsis and COVID-19 conditions: implications for managing severe COVID-19 patients. Front Immunol 2021;12:602848.   DOI
19 Longstaff C. Measuring fibrinolysis: from research to routine diagnostic assays. J Thromb Haemostasis 2018;16(4):652-62.   DOI
20 Ibanez C, Perdomo J, Calvo A, Ferrando C, Reverter J, Tassies D, et al. High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? J Thromb Thrombolysis 2021;51(2):308-12.   DOI
21 Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol 2011;696:291-303.   DOI
22 Pelzl L, Singh A, Funk J, Witzemann A, Marini I, Zlamal J, et al. Antibody-mediated procoagulant platelet formation in COVID-19 is AKT dependent. J Thromb Haemost 2021.
23 Basile MS, Cavalli E, McCubrey J, Hernandez-Bello J, Munoz-Valle JF, Fagone P, et al. The PI3K/Akt/mTOR pathway: a potential pharmacological target in COVID-19. Drug Discov Today 2021;S1359-6446(21):480-3.
24 Abu-Eid R, Ward FJ. Targeting the PI3K/Akt/mTOR pathway: a therapeutic strategy in COVID-19 patients. Immunol Lett 2021;240:1-8.   DOI
25 Schmitt FCF, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care 2019;9(1):19.   DOI
26 Korkmaz H. Could sumac be effective on COVID-19 treatment? J Med Food 2021;24(6):563-8.   DOI
27 van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009;85(2):195-204.   DOI
28 Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, De Gaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res 2012;129(3):263-6.   DOI
29 Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res 2018;122(2):337-51.   DOI
30 Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197(11):1585-98.   DOI
31 Jeong D, Irfan M, Kim S-D, Kim S, Oh J-H, Park C-K, et al. Ginsenoside Rg3-enriched red ginseng extract inhibits platelet activation and in vivo thrombus formation. J Ginseng Res 2017;41(4):548-55.   DOI
32 Abu-Farha M, Al-Sabah S, Hammad MM, Hebbar P, Channanath AM, John SE, et al. Prognostic genetic markers for thrombosis in COVID-19 patients: a focused analysis on D-dimer, homocysteine and thromboembolism. Front Pharmacol 2020;11:587451.   DOI
33 Dong J-f, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100(12):4033-9.   DOI
34 Mulder R, Croles FN, Mulder AB, Huntington JA, Meijer K, Lukens MV. SERPINC 1 gene mutations in antithrombin deficiency. Br J Haematol 2017;178(2):279-85.   DOI
35 Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminf 2014;6:13.   DOI
36 Irfan M, Kim M, Rhee MH. Anti-platelet role of Korean ginseng and ginsenosides in cardiovascular diseases. J Ginseng Res 2020;44(1):24-32.   DOI
37 Thim T, Hagensen M, Bentzon J, Falk E. From vulnerable plaque to atherothrombosis. J Intern Med 2008;263(5):506-16.   DOI
38 Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S, et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg 2020;231(2):193-203.   DOI
39 Barrett TJ, Cornwell M, Myndzar K, Rolling CC, Xia Y, Drenkova K, et al. Platelets amplify endotheliopathy in COVID-19. Sci Adv 2021;7(37):eabh2434.   DOI
40 Liu Z, Guo F, Wang Y, Li C, Zhang X, Li H, et al. BATMAN-TCM: a bioinformatics analysis tool for molecular mechANism of traditional Chinese medicine. Sci Rep 2016;6:21146.   DOI
41 Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res 2019;18(2):623-32.   DOI
42 Liu X, Li Z, Liu S, Sun J, Chen Z, Jiang M, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B 2020;10(7):1205-15.   DOI
43 Mohamed-Hussein AA, Aly KM, Ibrahim M-EA. Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? Med Hypotheses 2020;144:109975.   DOI
44 Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol 2021;96(4):471-9.   DOI
45 Salah HM, Mehta JL. Meta-analysis of the effect of aspirin on mortality in COVID-19. Am J Cardiol 2021;142:158-9.   DOI
46 Cipolloni L, Sessa F, Bertozzi G, Baldari B, Cantatore S, Testi R, et al. Preliminary post-mortem COVID-19 evidence of endothelial injury and factor VIII hyper-expression. Diagnostics 2020;10(8):575.   DOI
47 Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17(5):259-60.   DOI
48 Lee YY, Kim SD, Park S-C, Rhee MH. Panax ginseng: inflammation, platelet aggregation, thrombus formation, and atherosclerosis crosstalk. J Ginseng Res 2021. Article in Press.
49 Kwon HW, Shin JH, Lee DH, Park HJ. Inhibitory effects of cytosolic Ca(2+) concentration by ginsenoside Ro are dependent on phosphorylation of IP3RI and dephosphorylation of ERK in human platelets. Evid Based Complement Alternat Med 2015;2015:764906.
50 Cho I-H, Kang B-W, Yun-Jae P, Lee H-J, Park S, Lee N. Ginseng berry extract increases nitric oxide level in vascular endothelial cells and improves cGMP expression and blood circulation in muscle cells. J Exerc Nutrition Biochem 2018;22(3):6-13.   DOI
51 Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pao CR, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood 2020;136(11):1330-41.   DOI
52 Panyod S, Ho C-T, Sheen L-Y. Dietary therapy and herbal medicine for COVID-19 prevention: a review and perspective. J Tradit Complement Med 2020;10(4):420-7.   DOI
53 Lacour T, Semaan C, Genet T, Ivanes F. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients. Cathet Cardiovasc Interv 2021;97(2):E241-3.
54 Irfan M, Kwak Y-S, Han C-K, Hyun SH, Rhee MH. Adaptogenic effects of Panax ginseng on modulation of cardiovascular functions. J Ginseng Res 2020;44(4):538-43.   DOI
55 Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J Mol Histol 2020;51(6):613-28.   DOI
56 Medcalf RL, Keragala CB, Myles PS. Fibrinolysis and COVID-19: a plasmin paradox. J Thromb Haemostasis 2020;18(9):2118-22.   DOI
57 Conti P, Caraffa A, Gallenga C, Ross R, Kritas S, Frydas I, et al. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and microthrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J Biol Regul Homeost Agents 2020;34(5):1623-7.
58 Sangkuhl K, Shuldiner AR, Klein TE, Altman RB. Platelet aggregation pathway. Pharmacogenetics Genom 2011;21(8):516-21.   DOI
59 Lishko VK, Podolnikova NP, Yakubenko VP, Yakovlev S, Medved L, Yadav SP, et al. Multiple binding sites in fibrinogen for integrin aMb2 (Mac-1). J Biol Chem 2004;279(43):44897-906.   DOI
60 Wagner DD. P-selectin chases a butterfly. J Clin Invest 1995;95(5):1955-6.   DOI
61 Le Joncour A, Biard L, Vautier M, Bugaut H, Mekinian A, Maalouf G, et al. Neutrophil-platelet and monocyteeplatelet aggregates in COVID-19 patients. Thromb Haemostasis 2020;120(12):1733-5.   DOI
62 Leppkes M, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 2020;58:102925.   DOI
63 Singh NA, Kumar P, Kumar N. Spices and herbs: potential antiviral preventives and immunity boosters during COVID-19. Phytother Res 2021;35:2745-57.   DOI
64 Ang L, Lee HW, Kim A, Lee MS. Herbal medicine for the management of COVID-19 during the medical observation period: a review of guidelines. Integr Med Res 2020;9(3):100465.   DOI
65 Shahzad F, Anderson D, Najafzadeh M. The antiviral, anti-inflammatory effects of natural medicinal herbs and mushrooms and SARS-CoV-2 infection. Nutrients 2020;12(9):2573.   DOI
66 Gautam S, Gautam A, Chhetri S, Bhattarai U. Immunity against COVID-19: potential role of Ayush Kwath. J Ayurveda Integr Med 2022;13(1):100350.   DOI
67 Shin J-H, Kwon H-W, Rhee MH, Park H-J. Inhibitory effects of total saponin Korean red ginseng on thromboxane A 2 production and P-selectin expression via suppressing mitogen-activated protein kinases. Biomed Sci Letters 2017;23:310-20.   DOI
68 Son Y-M, Jeong D-H, Park H-J, Rhee M-H. The inhibitory activity of ginsenoside Rp4 in adenosine diphosphate-induced platelet aggregation. J Ginseng Res 2017;41(1):96-102.   DOI
69 Price LC, McCabe C, Garfield B, Wort SJ. Thrombosis and COVID-19 pneumonia: the clot thickens. Eur Respir J 2020;56(1):2001608.   DOI
70 Barrett TJ, Bilaloglu S, Cornwell M, Burgess HM, Virginio VW, Drenkova K, et al. Platelets contribute to disease severity in COVID-19. J Thromb Haemostasis 2021;19(12):3139-53.   DOI
71 Shin J-H, Kwon H-W, Irfan M, Rhee MH, Lee D-H. Ginsenoside Rk1 suppresses platelet mediated thrombus formation by downregulation of granule release and αIIbβ3 activation. J Ginseng Res 2021;45(4):490-7.   DOI
72 Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998;91(8):2645-57.   DOI
73 Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008;205(9):2065-74.   DOI
74 Kim J, Lee KP, Kim M-R, Kim BS, Moon BS, Shin CH, et al. A network pharmacology approach to explore the potential role of Panax ginseng on exercise performance. Phys Act Nutr 2021;25(3):28-35.   DOI
75 Jeon BR, Kim SJ, Hong SB, Park H-J, Cho JY, Rhee MH. The inhibitory mechanism of crude saponin fraction from Korean Red Ginseng in collagen-induced platelet aggregation. J Ginseng Res 2015;39(3):279-85.   DOI
76 Endale M, Lee W, Kamruzzaman S, Kim S, Park J, Park M, et al. Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation. Br J Pharmacol 2012;167(1):109-27.   DOI
77 Durrant TN, van den Bosch MT, Hers I. Integrin αIIbβ3 outside-in signaling. Blood 2017;130(14):1607-19.   DOI
78 Dhawan RT, Gopalan D, Howard L, Vicente A, Park M, Manalan K, et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir Med 2021;9(1):107-16.   DOI
79 Willyard C. Coronavirus blood-clot mystery intensifies. Nature 2020;581(7808):250.   DOI
80 Al-Hakeim HK, Al-Hamami S, Maes M. Increased serum thromboxane A2 and prostacyclin but lower complement C3 and C4 levels in COVID-19: associations with chest CT-scan anomalies and lowered peripheral oxygen saturation. medRxiv; 2021. Article in Press.
81 Hamming I, Timens W, Bulthuis M, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203(2):631-7.   DOI
82 Irfan M, Jeong D, Kwon H-W, Shin J-H, Park S-J, Kwak D, et al. Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling. Vasc Pharmacol 2018;109:45-55.   DOI
83 Irfan M, Jeong D, Saba E, Kwon H-W, Shin J-H, Jeon B-R, et al. Gintonin modulates platelet function and inhibits thrombus formation via impaired glycoprotein VI signaling. Platelets 2019;30(5):589-98.   DOI
84 Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol 2020;13(1):120.   DOI
85 Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010;47(13):2170-5.   DOI
86 Newby AC, George SJ, Ismail Y, Johnson JL, Sala-Newby GB, Thomas AC. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemostasis 2009;101(6):1006-11. 0.   DOI
87 Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020;26(7):1017-32.   DOI
88 Osborne TF, Veigulis ZP, Arreola DM, Mahajan SM, Roosli E, Curtin CM. Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS One 2021;16(2):e0246825.   DOI
89 Moroni F, Baldetti L. COVID-19 and arterial thrombosis: a potentially fatal combination. Int J Cardiol 2021;322:286-90.   DOI
90 Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev 2018;98(1):503-53.
91 Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID-19. Blood 2020;136(11):1317-29.   DOI
92 Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 2008;295(6):H2373-9.